Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases

Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Respirol Case Rep
Glavni autori: Takeda, Takayuki, Itano, Hideki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2017
Teme:
Case Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412970/
https://ncbi.nlm.nih.gov/pubmed/28469919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.241
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items